Payment overview · 2025
General Payments
$255.36
9 reported records · 5 companies
Healthcare provider profile · identity verified
Collette R Fox, MLP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SHELBY, NC · NPI 1578842332
Verified facts
What the public records show
CMS Open Payments records show Collette R Fox, MLP received $255.36 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $98.17 | 38.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.67 | 25.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.09 | 19.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.98 | 10.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.45 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $255.36 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $98.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.67 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.09 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
178 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 119 |
| Lisinopril | Lisinopril | 395 | 100 |
| Omeprazole | Omeprazole | 377 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 81 |
| Escitalopram Oxalate | Escitalopram Oxalate | 291 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 58 |
| Losartan Potassium | Losartan Potassium | 248 | 56 |
| Spironolactone | Spironolactone | 244 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 50 |
| Ozempic | Semaglutide | 178 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 45 |
| Simvastatin | Simvastatin | 169 | 44 |
| Lorazepam | Lorazepam | 162 | 33 |
| Gabapentin | Gabapentin | 161 | 48 |
| Azithromycin | Azithromycin | 154 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 42 |
| Clonazepam | Clonazepam | 139 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 35 |
| Metformin Hcl Er | Metformin Hcl | 137 | 39 |
| Metformin Hcl | Metformin Hcl | 133 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 34 |
| Furosemide | Furosemide | 130 | 41 |
| Allopurinol | Allopurinol | 129 | 30 |
| Eliquis | Apixaban | 125 | 27 |
| Methylprednisolone | Methylprednisolone | 124 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 30 |
| Montelukast Sodium | Montelukast Sodium | 116 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 30 |
| Alprazolam | Alprazolam | 102 | 17 |
| Carvedilol | Carvedilol | 102 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 18 |
| Potassium Chloride | Potassium Chloride | 85 | 25 |
| Famotidine | Famotidine | 79 | 20 |
| Farxiga | Dapagliflozin Propanediol | 77 | 14 |
| Prednisone | Prednisone | 77 | 29 |
| Meloxicam | Meloxicam | 74 | 12 |
| Bupropion Xl | Bupropion Hcl | 72 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 13 |
| Tramadol Hcl | Tramadol Hcl | 67 | 17 |
| Jardiance | Empagliflozin | 61 | 13 |
| Sertraline Hcl | Sertraline Hcl | 60 | suppressed |
| Xarelto | Rivaroxaban | 60 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 51 | suppressed |
| Ramipril | Ramipril | 48 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Diazepam | Diazepam | 41 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 21 |
| Glimepiride | Glimepiride | 40 | 14 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 20 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 16 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Trazodone Hcl | Trazodone Hcl | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 11 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Estradiol | Estradiol | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 14 |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ritonavir | Ritonavir | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $255.36 · 9 records | Exact Sciences Corporation | AREXVY, BREZTRI, Cologuard Collection Kit, SHINGRIX, WaveWriter Alpha Prime 16, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error